Teacher Retirement System of Texas Purchases New Holdings in Immunome, Inc. (NASDAQ:IMNM)

Teacher Retirement System of Texas bought a new position in Immunome, Inc. (NASDAQ:IMNM) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 11,648 shares of the company’s stock, valued at approximately $124,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its position in Immunome by 217.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock valued at $6,469,000 after purchasing an additional 302,916 shares in the last quarter. Geode Capital Management LLC raised its stake in Immunome by 13.6% in the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock valued at $17,657,000 after buying an additional 144,557 shares during the last quarter. Magnus Financial Group LLC boosted its holdings in Immunome by 107.8% in the fourth quarter. Magnus Financial Group LLC now owns 53,536 shares of the company’s stock worth $569,000 after acquiring an additional 27,777 shares in the last quarter. Point72 Asset Management L.P. grew its stake in shares of Immunome by 22.2% during the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock worth $6,881,000 after acquiring an additional 85,580 shares during the last quarter. Finally, Barclays PLC raised its position in shares of Immunome by 125.9% in the 3rd quarter. Barclays PLC now owns 105,886 shares of the company’s stock valued at $1,547,000 after purchasing an additional 59,016 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Price Performance

Immunome stock opened at $6.71 on Thursday. The stock has a market cap of $583.44 million, a PE ratio of -0.83 and a beta of 1.93. Immunome, Inc. has a 1-year low of $6.19 and a 1-year high of $22.03. The stock’s fifty day moving average is $9.29 and its two-hundred day moving average is $11.13.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The business had revenue of $2.74 million during the quarter, compared to analysts’ expectations of $3.07 million. On average, research analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Insider Transactions at Immunome

In other news, CTO Philip Tsai bought 12,300 shares of Immunome stock in a transaction on Monday, March 24th. The shares were bought at an average cost of $8.42 per share, for a total transaction of $103,566.00. Following the acquisition, the chief technology officer now owns 33,300 shares in the company, valued at approximately $280,386. This trade represents a 58.57 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Clay B. Siegall purchased 150,000 shares of Immunome stock in a transaction on Friday, January 31st. The shares were acquired at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares in the company, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 306,400 shares of company stock worth $2,322,995 over the last ninety days. 8.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have commented on the company. Lifesci Capital started coverage on Immunome in a research report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price target for the company. Wedbush restated an “outperform” rating and set a $33.00 price target on shares of Immunome in a research report on Thursday, March 20th. Stephens reaffirmed an “overweight” rating and set a $30.00 price objective on shares of Immunome in a research note on Thursday, March 20th. Lake Street Capital assumed coverage on shares of Immunome in a research note on Wednesday. They set a “buy” rating and a $23.00 target price on the stock. Finally, Guggenheim dropped their target price on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, March 20th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $25.14.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.